Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Korro Bio, a clinical-stage biopharmaceutical company focused on developing genetic medicines through RNA editing, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisco.
Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the conference. Other key executives, including Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate.
A live webcast of the presentation will be available on the “Events & Presentations” page in the Investor section of Korro’s website (www.korrobio.com). A replay of the event will be accessible for 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – KRRO
In the trading session that priced this news, KRRO declined 7.23%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisco. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference.
A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investor & Media Contact
Tim Palmer
IR@korrobio.com
